Presentations

      Assessing the Impact of Switching to the Tobacco Heating System on Cardiovascular Events: Translating Basic Science into Clinical Benefit

      Pater, C.

      Conference date
      Mar 3, 2019
      Conference name

      The 6th International Conference on Prehypertension, Hypertension, Metabolic Disorders and Cardiovascular Disease 2019
      Link to more information
      Topic
      Summary

      Introduction: Cigarette smoking contributes to the development of cardiovascular disease (CVD). Philip Morris International’s (PMI) Tobacco Heating System (THS) is a novel tobacco product that heats tobacco instead of burning it, thereby generating lower levels of harmful and potentially harmful constituents (cardiovascular toxicants are reduced by more than 92%) compared with cigarette smoke (CS). Methods: Philip Morris International’s (PMI) assessment program aims to demonstrate that switching to THS has the potential to reduce the risk of smoking-related diseases versus continued smoking. The program includes in vitro/in vivo toxicology studies that follow OECD guidelines, Good Laboratory Practice, and a systems toxicology approach, and randomized, clinical studies following the principles of Good Clinical Practice. Results: The effects of THS aerosol on the adhesion of monocytic cells to human coronary endothelial cells are significantly reduced, and switching to THS halted the progression of CS-induced atherosclerotic changes in ApoE-/- mice. Endpoints linked to the development of smoking-related disease were analyzed following a sixmonth randomized, controlled clinical study with THS that demonstrated a consistent improvement of endpoints in different pathophysiologic pathways leading to atherosclerosis. Conclusions: The evidence available to date indicates that switching to THS has the potential to reduce the risk of CVD. As a next step, PMI will be complementing its THS assessment program with cardiovascular outcome studies intended to demonstrate the clinical benefit of switching to THS (e.g., reduction in the risk of cardiovascular death, myocardial infraction, and stroke) as compared with continuous smoking. This cardiovascular outcome study program will improve primary and secondary CVD prevention in clinical practice.

      Related Publications

      Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking

      Clinical

      Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America

      Clinical

      Reduced exposure to Harmful and Potentially Harmful Constituents after 90 days of use of Tobacco Heating System 2.2 Menthol in Japan: A comparison with continued cigarette use or smoking abstinence

      Clinical

      Reduced Exposure To Harmful And Potentially Harmful Constituents after 90 Days Of Use Of Tobacco Heating System 2.2 Menthol In Japan: A Comparison With Continued Cigarette Use Or Smoking Abstinence

      Clinical

      Psychometric Evaluation of the mCEQ applied to Cigarettes and Heat-Not-Burn Products in the US and Japan

      Clinical

      Pharmacokinetics Of Nicotine And Subjective Effects Following The Single Use Of A Non-Menthol And Menthol Version Of Tobacco Heating System 2.2 In Two Studies In Japan: A Comparison With Single Use Of A Combustible Cigarette And Nicotine Gum

      Clinical

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.